$ALPMY News Article - Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV (enfortumab vedotin-ejfv) and KEYTRUDA (pembrolizumab) in First-Line Advanced Bladder Cancer
https://marketwirenews.com/news-releases/grou...53531.html